[go: up one dir, main page]

NO991678D0 - Sulfonamid-substituerte asparaginsyre-interleukin-1<beta>-omdannelsesenzym-inhibitorer - Google Patents

Sulfonamid-substituerte asparaginsyre-interleukin-1<beta>-omdannelsesenzym-inhibitorer

Info

Publication number
NO991678D0
NO991678D0 NO991678A NO991678A NO991678D0 NO 991678 D0 NO991678 D0 NO 991678D0 NO 991678 A NO991678 A NO 991678A NO 991678 A NO991678 A NO 991678A NO 991678 D0 NO991678 D0 NO 991678D0
Authority
NO
Norway
Prior art keywords
pct
beta
interleukin
sulfonamide
aspartic acid
Prior art date
Application number
NO991678A
Other languages
English (en)
Other versions
NO315042B1 (no
NO991678L (no
Inventor
Hamish John Allen
Kenneth Dale Brady
William Glen Harter
Elizabeth Ann Lunney
Mark Stephen Plummer
Tomi Sawyer
Aurash Shahripour
Nigel Walker
Original Assignee
Warner Lambert Co
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Basf Ag filed Critical Warner Lambert Co
Publication of NO991678D0 publication Critical patent/NO991678D0/no
Publication of NO991678L publication Critical patent/NO991678L/no
Publication of NO315042B1 publication Critical patent/NO315042B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Furan Compounds (AREA)
NO19991678A 1996-10-11 1999-04-09 Sulfonamid-substituerte asparaginsyre-interleukin-1<beta>- omdannelsesenzym-inhibitorer, anvendelse derav og farmasöytiske preparaterinneholdende disse forbindelser NO315042B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2832396P 1996-10-11 1996-10-11
PCT/US1997/018406 WO1998016504A2 (en) 1996-10-11 1997-10-09 SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS

Publications (3)

Publication Number Publication Date
NO991678D0 true NO991678D0 (no) 1999-04-09
NO991678L NO991678L (no) 1999-04-12
NO315042B1 NO315042B1 (no) 2003-06-30

Family

ID=21842812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991678A NO315042B1 (no) 1996-10-11 1999-04-09 Sulfonamid-substituerte asparaginsyre-interleukin-1<beta>- omdannelsesenzym-inhibitorer, anvendelse derav og farmasöytiske preparaterinneholdende disse forbindelser

Country Status (14)

Country Link
US (1) US6083981A (no)
EP (1) EP0932600B1 (no)
JP (1) JP2001502330A (no)
KR (1) KR20000049050A (no)
AT (1) ATE317381T1 (no)
AU (1) AU742746B2 (no)
BR (1) BR9713314A (no)
CA (1) CA2268103A1 (no)
DE (1) DE69735230D1 (no)
IL (1) IL129124A0 (no)
NO (1) NO315042B1 (no)
NZ (1) NZ334887A (no)
PL (1) PL332704A1 (no)
WO (1) WO1998016504A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1800176A (zh) * 2000-12-13 2006-07-12 惠氏 β淀粉样蛋白产生的杂环磺酰胺类抑制剂
EP1392280A4 (en) * 2001-05-10 2005-11-30 Warner Lambert Co ARYLSULFONAMIDE ETHERS AND METHODS OF USE THEREOF
JP4502580B2 (ja) * 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのil−18阻害剤の使用
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
EP2374792A1 (en) * 2004-03-11 2011-10-12 Elan Pharmaceuticals Inc. N-substituted benzene sulfonamides
CN102362867A (zh) 2004-05-15 2012-02-29 沃泰克斯药物股份有限公司 使用ice抑制剂治疗癫痫发作
EP1752159A4 (en) * 2004-05-17 2009-07-01 Univ Keio MEDICAL COMPOSITION AND THERAPEUTIC PROCEDURE
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
JP2010535167A (ja) 2007-08-03 2010-11-18 サノフィ−アベンティス カスパーゼイメージングプローブ
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
EP2635906A4 (en) 2010-11-05 2014-04-02 Univ Brandeis Ice inhibiting compounds and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP2848696A1 (en) 2013-09-13 2015-03-18 Sanofi-Aventis Deutschland GmbH Caspase-1 imaging probes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0519748B1 (en) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
WO1995026958A1 (en) * 1994-03-31 1995-10-12 Sanofi Winthrop, Inc. Pyrimidinyl derivatives as interleukin inhibitors
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme

Also Published As

Publication number Publication date
AU742746B2 (en) 2002-01-10
PL332704A1 (en) 1999-09-27
EP0932600A2 (en) 1999-08-04
WO1998016504A2 (en) 1998-04-23
BR9713314A (pt) 2000-01-25
JP2001502330A (ja) 2001-02-20
ATE317381T1 (de) 2006-02-15
EP0932600B1 (en) 2006-02-08
NZ334887A (en) 2000-09-29
DE69735230D1 (de) 2006-04-20
IL129124A0 (en) 2000-02-17
NO315042B1 (no) 2003-06-30
CA2268103A1 (en) 1998-04-23
KR20000049050A (ko) 2000-07-25
WO1998016504A3 (en) 1998-06-25
US6083981A (en) 2000-07-04
AU4817297A (en) 1998-05-11
NO991678L (no) 1999-04-12

Similar Documents

Publication Publication Date Title
NO991674D0 (no) Interleukin-1&lt;Beta&gt;omdannelsesenzym-inhibitor-sulfonamider
PT1049703E (pt) Aldeido do acido n-¬2-(5-benziloxicarbonilamino-6-oxo-2-(4-fluorofenil)-1,6-di-hidro-1-pirimidinil)acetoxil|-l-aspartico como inibidor da enzima de conversao da interleucina-1beta in vivo
NO991678D0 (no) Sulfonamid-substituerte asparaginsyre-interleukin-1&lt;beta&gt;-omdannelsesenzym-inhibitorer
ATE240103T1 (de) Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori
EA200400648A1 (ru) N, n&#39;-замещенные производные 1,3-диамино-2-гидроксипропана
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
PT752987E (pt) Derivados de pirimidinilo como inibidores da interleucina
ATE310011T1 (de) Inhibitoren des interleukin-1-beta konvertierenden enzyms
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
BR9911010A (pt) Inibidores de sucinamida de enzima de conversão da interleucina-1beta
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
WO2002089749A3 (en) Arylsulfonamide ethers, and methods of use thereof
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
BG107051A (en) Method for the preparation of citalopram
DK1165491T3 (da) LTA4-hydrolase-inhibitorer
DE60204014D1 (de) Chlormethylierung von thiophene
BR0015482A (pt) Antagonistas de difenil leucotrieno de heterociclo substituìdo
BR9612000A (pt) Naftil glioxamidas como inibidores de spla; &#39;

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees